RxDoctor Payments Data

Catherine Marti, MD

Advanced Heart Failure and Transplant Cardiology · Athens, GANPI 1124203989

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $273,105 of the $343,402 with a category attached, or 79.5%. 29 manufacturers reported payments, led by AstraZeneca at 32.1% of the total. Among advanced heart failure and transplant cardiology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$343,402in general payments, 2019–2025

Across 554 payments — averaging $619.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$110K
  • Pfizer$92K
  • Novartis$56K
  • Merck$43K
  • Boehringer Ingelheim$17K
  • Bayer$10K
  • plus $16K from 23 others
$308,519in research payments, 2019–2025

Across 62 payments — averaging $4976.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$166K
  • Endotronix, Inc.$124K
  • American Regent$18K
  • Amgen$812

What the payments were for

  • Consulting fees$44,65213%
  • Speaking & faculty fees$273,10580%
  • Travel & lodging$15,1104%
  • Food & beverage$10,4033%
  • Education$1320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$343,402 in reported general payments places this provider in the 95th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.

See all advanced heart failure and transplant cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$139,854
Medicare patients
652
Services billed
1,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis49$2,192,219
EntrestoSacubitril/Valsartan774$1,018,956
FarxigaDapagliflozin Propanediol606$733,222
VyndaqelTafamidis Meglumine28$621,905
EliquisApixaban444$467,325
JardianceEmpagliflozin338$402,404
XareltoRivaroxaban107$125,967
VerquvoVericiguat74$109,580
Repatha SureclickEvolocumab63$62,799
Eplerenone177$16,978
BrilintaTicagrelor19$14,702
Metoprolol Succinate744$10,216
Torsemide351$7,929
DapagliflozinDapagliflozin Propanediol14$6,358
Spironolactone706$4,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$92,343$3,281,449521 claims
NovartisEntresto$55,743$1,018,956774 claims
AstraZenecaFarxiga, Brilinta$110,092$747,925625 claims
Boehringer IngelheimJardiance$16,820$402,404338 claims
Johnson & JohnsonXarelto$75$125,967107 claims
MerckVerquvo$42,548$109,58074 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.

Other advanced heart failure and transplant cardiology in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →